Why Do Some Patients Receiving Chemotherapy Never Experience Nausea?
In this article
Emetic Resistance and Freedom from Symptoms During Cancer Treatment
A multidimensional analysis of why some patients never experience nausea, even with chemotherapy that carries a high emetic risk.
1. Emetogenic Potential: The First Barrier
The first determinant of a nausea-free course is the direct effect of the drugs used on the gastric mucosa and the brain’s “vomiting center.” Modern oncology classifies drugs by these effects, establishing a protective shield from the very start of treatment:
| Category | Incidence of Vomiting (Without Prophylaxis) | Key Mechanism | Example Regimens |
|---|---|---|---|
| High Risk (HEC) | > %90 | Excessive release of serotonin and substance P | Cisplatin, Anthracycline + Cyclophosphamide (AC) |
| Moderate Risk (MEC) | %30 - %90 | Neurokinin predominance in the delayed phase | Oxaliplatin, Carboplatin, Irinotecan |
| Low Risk (LEC) | %10 - %30 | Mild mucosal irritation | Paclitaxel, Gemcitabine, 5-FU |
| Minimal Risk | < %10 | Low toxicity with targeted treatment | Monoclonal Antibodies, Immunotherapies |
2. Neurobiological “Silence”: Why Is the Signal Interrupted?
The sensation of nausea results from communication between the digestive system and the brain. In patients described as “lucky,” this communication pathway is either genetically weak or completely blocked by drugs:
During the first 24 hours after chemotherapy, large amounts of serotonin (5-HT) are released from the intestines. In patients who do not experience nausea:
- Receptor Resistance: The 5-HT3 receptors on the vagus nerve are less sensitive to serotonin.
- Rapid Clearance: The released serotonin is cleared from the synaptic space much faster for genetic reasons.
- Successful Prophylaxis: Modern agents such as palonosetron “occupy” the receptor for 40 hours, leaving no room for serotonin.
Acting after the first 24 hours, substance Pstimulates NK1 receptors in the brainstem. In resistant patients:
- Fewer Receptors: NK1 receptor density is low in the brain’s vomiting center (the area postrema).
- Barrier Strength: The blood-brain barrier is less permeable to emetic stimuli entering the brain.
- NK1 Antagonists: Drugs such as aprepitant completely disrupt the key-and-lock fit of substance P.
3. Pharmacogenetics: The Hidden Protection in DNA
The deepest explanation for why some patients do not vomit is their capacity to process antiemetic drugs. Their liver and brain systems are coded to derive maximum benefit from these drugs:
The ABCB1 Gene: How Long the Drug Remains in the Brain
For antiemetics to work, they must remain in the brain’s vomiting center for a sufficient length of time. The ABCB1 genecontrols the P-glycoprotein (P-gp) pump, which removes the drug from the brain:
| Genotype Variant | P-gp Pump Activity Rate | Outcome |
|---|---|---|
| CC Genotype | Very Fast (Rapidly Pumps the Drug Out) | Greater risk of nausea |
| TT Genotype | Slow (The Drug Is Trapped in the Brain) | Perfect protection and zero nausea |
CYP2D6: Metabolic Luck
If a patient is genetically a “poor metabolizer,” their liver breaks down antiemetic drugs very slowly. Although this may appear disadvantageous, it is an advantage in the context of CINV: the drug remains at a high concentration in blood and tissues for much longer than in a typical patient, providing protection.
4. Psychological Resilience and the Alcohol Paradox
Alongside physical mechanisms, the brain’s “learning” and “expectation” processes also play a role in freedom from symptoms:
Breaking the Conditioning: Most patients who do not experience nausea are those who received very strong antiemetic treatment during their first cycle. Once the brain avoids forming the association “chemotherapy = nausea,” “anticipatory nausea” is not triggered in later cycles.
The Effect of Alcohol: Chronic alcohol use desensitizes dopamine and GABA receptors in the brain, raising the activation threshold of the emetic center. These patients have a more “stoic” nervous system in the face of toxins.
DROZDOGAN Academy Commentary
In modern oncology, success is measured not only by eliminating the tumor but also by avoiding sacrificing even a single day of the patient’s quality of life. The fact that some patients go through this process without symptoms proves that we can manage the possibilities offered by biology with pharmacological precision. Our central vision for the future is to read each patient’s genetic profile in advance and include everyone in this group of “fortunate freedom from symptoms.”
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.